Advances in delivery technology and manufacturing costs have driven a surge of activity in peptide drug development, says Thomas Früh, CEO of Bachem - the largest and most advanced peptide drug CMO in the world.
Peptide therapeutics are a hot topic in the pharma industry today – what’s the story behind the emergence of this thriving niche?
"Our slogan is “Pioneering Partner for Peptides” and this says it all – we were the first CMO to bring peptide APIs to the market, and today represent the leading edge of technology in the field with the most advanced technological capabilities which allow us to synthesize the largest peptides economically. "
